Viral safety and inhibitor development associated with monoclonal antibody-purified F VIII C
- 1 September 1991
- journal article
- Published by Springer Nature in Annals of Hematology
- Vol. 63 (3) , 138-141
- https://doi.org/10.1007/bf01703244
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Low Risk for Hepatitis C in Hemophiliacs Given a High-Purity, Pasteurized Factor VIII ConcentrateAnnals of Internal Medicine, 1990
- Human anti-mouse immunoglobulins in sera of patients treated chronically with monoclonal antibody-purified factor VIII.1990
- Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in hemophiliacs previously unexposed to factor VIIIC concentrates. The Monoclate Study Group.1990
- Revision of the Protocol Recommended for Studies of Safety from Hepatitis of Clotting Factor ConcentratesThrombosis and Haemostasis, 1989
- Revision of the protocol recommended for studies of safety from hepatitis of clotting factor concentrates. International Society for Thrombosis and Hemostasis.1989
- VIRUCIDAL TREATMENT OF CLOTTING FACTOR CONCENTRATESThe Lancet, 1988
- Absence of Hepatitis after Treatment with a Pasteurized Factor VIII Concentrate in Patients with Hemophilia and No Previous TransfusionsNew England Journal of Medicine, 1987
- Measurement of factor VIII inhibitors.1984
- Measurement of Mild Factor VIII Inhibitors in Bethesda UnitsThrombosis and Haemostasis, 1975